V
Vivek Makwana
Researcher at Griffith University
Publications - 9
Citations - 319
Vivek Makwana is an academic researcher from Griffith University. The author has contributed to research in topics: Prostate cancer & Doxorubicin. The author has an hindex of 5, co-authored 9 publications receiving 186 citations.
Papers
More filters
Journal ArticleDOI
Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach.
TL;DR: The results from lymphatic transport and tissue distribution study indicate that a significant part of the EFV had by-passed portal system and was recovered in the lymph via chylomicron uptake mechanism, indicating that major amount of EFV bypasses the liver and thereby, enhances the oral bioavailability of theEFV.
Journal ArticleDOI
Peptides, Peptidomimetics, and Carbohydrate–Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer’s Disease
Philip Ryan,Bhautikkumar Patel,Vivek Makwana,Hemant R. Jadhav,Milton J. Kiefel,Andrew K. Davey,Tristan A. Reekie,Santosh Rudrawar,Michael Kassiou +8 more
TL;DR: Advances made in the last 5 years are reviewed, as well as the arrival of sugar-based derivatives within the AD field.
Journal ArticleDOI
Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization.
Vivek Makwana,Jasmine D. Karanjia,Thomas Haselhorst,Shailendra Anoopkumar-Dukie,Santosh Rudrawar +4 more
TL;DR: There is ample scope for further improvement in the efficiency of targeting tumors by coupling biological active ligands onto the liposome surface to generate intelligent drug delivery systems.
Journal ArticleDOI
Essential role of O-GlcNAcylation in stabilization of oncogenic factors.
TL;DR: The focus of this article is to highlight the interplay between oncogenic factors and O-GlcNAcylation along with OGT in cancer cell proliferation and survival and the prospects for OGT inhibitors.
Journal ArticleDOI
Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY
TL;DR: This review highlights caprazamycins as promising lead structures for development of potent and selective antimicrobial agents that target MraY, the bacterial enzyme involved in the first membrane-dependent step in bacterial peptidoglycan assembly.